Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBI608 plus weekly paclitaxel versus placebo plus weekly paclitaxel in previously treated advanced gastric or gastroesophageal junction adenocarcinoma
2014-000774-18Phase 3Terminated
- Sponsor
- Boston Biomedical
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Napabucasin plus weekly paclitaxel with Placebo plus weekly paclitaxel (2 arms). Primary endpoint: Overall survival. Started Aug 2014; status: terminated.
02
Drugs
napabucasinpaclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2014-000774-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000774-18.